Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Shanghai Pharmaceuticals Holding Co ( (HK:2607) ) has provided an update.
Shanghai Pharmaceuticals Holding Co., Ltd. has proposed a final ordinary cash dividend of RMB 3.5 per 10 shares for the financial year ended 31 December 2025, subject to shareholder approval. Key timetable details, including the record date, ex-dividend date, payment date and the default payment currency for Hong Kong investors, will be announced in due course.
The company also outlined the withholding tax arrangements for different categories of H-shareholders, distinguishing between mainland resident enterprises, overseas non-resident enterprises, Hong Kong and Macau residents, and other non-resident individuals. Tax withholding rates will generally be 10% or 20% depending on shareholder status and the applicable tax treaties with the PRC, with mainland individual investors using Southbound Trading subject to a 20% rate on dividend income.
The most recent analyst rating on (HK:2607) stock is a Hold with a HK$13.00 price target. To see the full list of analyst forecasts on Shanghai Pharmaceuticals Holding Co stock, see the HK:2607 Stock Forecast page.
More about Shanghai Pharmaceuticals Holding Co
Shanghai Pharmaceuticals Holding Co., Ltd. is a major Chinese pharmaceutical group listed in Hong Kong, operating across the manufacture, distribution and retail of medicines and healthcare products. The company focuses on serving hospital, pharmacy and consumer markets in mainland China and overseas through its portfolio of prescription drugs, generics and related medical services.
YTD Price Performance: 0.70%
Average Trading Volume: 2,216,670
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$63.3B
See more data about 2607 stock on TipRanks’ Stock Analysis page.